Humerus Articles & Analysis
14 news found
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. “Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda’s proven track record makes her an excellent addition to the Daxor team ...
The rocking horse effect occurs when the humerus both rotates and translates on the scapula as it articulates. ...
Visit booth #2408 for product demonstrations of the Archer™ Shoulder Systems NAPLES, Fla., March 22, 2022 – Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, will be at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting, March 23-25, 2022, in Chicago. At booth #2408, Catalyst will have demos and the ...
GRAND RAPIDS, Mich., March 14, 2022—Shoulder Innovations LLC., (SI), a leading innovator in the development of shoulder replacement systems, announces the FDA Clearance of their latest component of the InSetTM Total Shoulder System, the InSetTM Stemless Humeral System. The InSetTM Stemless implant is the latest addition to the innovative and integrated InSetTM system, which already includes ...
RSIP Vision’s new tool utilizes the shoulder MRI scan, without compromising on resolution quality. It automatically segments the humerus and scapula from the scan. The segmentation output goes through another neural network, trained to upgrade segmentation resolution, thus producing a super-resolution model despite the original scan limitations. ...
HOLLAND, Mich., August 23, 2021 — Shoulder Innovations Inc, a leading innovator in the development of shoulder replacement systems, announced today that they have received FDA clearance for their InSet™ Reverse Shoulder Arthroplasty System. The InSet™ Reverse Shoulder system seamlessly integrates and rounds out a best in class product line for shoulder arthroplasty including: ...
In the US, the IlluminOss System is now indicated for use in skeletally mature patients in the treatment of traumatic, fragility, pathological, and impending pathological fractures of the humerus, radius, ulna, clavicle, pelvis, fibula, metacarpals, metatarsals, and phalanges. ...
In the US, the IlluminOss System was previously cleared by the FDA for the treatment of traumatic, fragility, pathological, and impending pathological fractures of the humerus, radius, ulna, clavicle, pelvis, metacarpals, metatarsals, and phalanges. ...
In the US, the IlluminOss System was previously cleared by the FDA for the treatment of traumatic, fragility, pathological, and impending pathological fractures of the humerus, radius, and ulna. IlluminOss can be also used in conjunction with FDA-cleared fracture fixation systems to provide supplemental fixation in compromised bone in all cleared anatomic sites. ...
Bone Stabilization System for use in skeletally mature patients in the treatment of traumatic and fragility fractures of the humerus, radius and ulna. IlluminOss recently obtained FDA clearance for these exciting new indications*, having been previously available solely for the treatment of pathological and impending pathological fractures associated with metastatic disease in ...
Food and Drug Administration (FDA) for use in skeletally mature patients in the treatment of traumatic, fragility, pathological, and impending pathological fractures of the humerus, radius and ulna. “IlluminOss’ minimally invasive approach isideal for treating patients suffering from fragility fractures. ...
Food and Drug Administration (FDA) de novo clearance for the IlluminOss Bone Stabilization System for treatment of impending and actual pathological fractures of the humerus, radius and ulna from metastatic bone disease. The IlluminOss System incorporates the use of a thin-walled PET balloon that is infused with a liquid monomer and delivered in a minimally invasive fashion into ...
IlluminOss’ LightFix Trial is a multi-center study of the IlluminOss System for the treatment of impending and actual pathological fractures in the humerus from metastatic bone disease Preliminary results from the U.S. trial measured pain and functional improvement, as well as evaluated safety and performance. ...
Thirteen surgical sites around the country participated in the trial, which included 80 patients - all with impending or pathologic fractures in the humerus due to metastatic carcinoma. IlluminOss’ minimally invasive procedure incorporates the use of a thin walled PET balloon that is infused with a liquid monomer and inserted into the intramedullary canal of the bone ...